Search Results 181-190 of 17343 for hba1c

1. A Study of the Effectiveness and Safety of Subcutaneous Semaglutide for Patients with Fatty-Liver Disease, not Caused by Alcoholism - Mayo Clinic

   HbA1c above 9% at screening; History or presence of pancreatitis (acute or chronic); Calcitonin equal or above 50 ng/L at screening; Family or personal history ...

2. A Study To Evaluate Bardoxolone Methyl In Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) - Mayo Clinic

   Uncontrolled diabetes (HbA1c > 11.0%) at Screen A visit. Serum albumin < 3 g/dL at Screen A visit. History of intracranial aneurysms. Kidney or any other ...

3. A Study Of The Effects Of Inflammation On Fat Tissue And Insulin In People With Different Body Shapes - Mayo Clinic

   For Type II Diabetic volunteers they will need a HbA1C between 7.0% and 9.5%. As with obese participants (above), transaminase, glucose and lipid values are ...

4. Safety Study Of OA-235i In Subjects With Nonalcoholic Steatohepatitis - Mayo Clinic

   Uncontrolled diabetes, defined as HbA1c of ≥ 9.5% within 60 days prior to Screening. History or presence of a compromised immune system including inherited ...

5. A Study Of The Use Of A New Drug In People With Non-Alcoholic Steatohepatitis (NASH) Or Non-Alcoholic Fatty Liver Disease (NAFLD) - Mayo Clinic

   Subjects with type 2 diabetes who are on stable doses of medications (except pioglitazone) to control hyperglycemia and have baseline HbA1c of 10% or lower.

6. CraniSeal Post Approval Study - Clinical Trials

   ... HbA1c elevation of \>9% despite standard diabetes care), * Patient has a documented, uncorrectable clinically significant coagulopathy (e.g., PTT\>37 ...

7. A Study To Evaluate The Effectiveness And Safety Of Elafibranor For Patients With Nonalcoholic Fatty Liver Disease - Mayo Clinic

   Decompensated diabetes (HbA1c>9%); A history of clinically significant acute cardiac event within 6 months prior to screening; Weight loss of more than 5 ...

8. A Study To Evaluate The Safety And Effectiveness Of TEPEZZA® In Treating Patients With Chronic (Inactive) Thyroid Eye Disease - Mayo Clinic

   Diabetic patients must have HbA1c ≤ 8.0% at Screening. Patients with a history of inflammatory bowel disease, ulcerative colitis or Crohn's disease must be ...

9. A Study To Evaluate Safety And Effectiveness Of G-POEM For Gastroparesis - Mayo Clinic

   Poorly controlled diabetes with HbA1c of greater than 10% at time of screening. New medications for gastroparesis-related symptoms started within 1 month ...

10. Mayo Clinic

    Fuel groundbreaking medical research! ... Your donation powers the future of medicine and helps save lives. Give Today.